Peapack-Gladstone Financial Corp’s Sarepta Therapeutics SRPT Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,191	Closed	-$587K	–	708
2025 Q1	$587K	Buy	9,191 +75	+0.8%	+$7.89K	0.01%	455
2024 Q4	$1.11M	Hold	9,116	–	–	0.02%	378
2024 Q3	$1.14M	Hold	9,116	–	–	0.02%	381
2024 Q2	$1.44M	Hold	9,116	–	–	0.02%	358
2024 Q1	$1.18M	Hold	9,116	–	–	0.02%	382
2023 Q4	$879K	Hold	9,116	–	–	0.01%	410
2023 Q3	$1.1M	Hold	9,116	–	–	0.02%	377
2023 Q2	$1.04M	Buy	9,116 +700	+8%	+$90.3K	0.02%	386
2023 Q1	$1.16M	Hold	8,416	–	–	0.02%	364
2022 Q4	$1.09M	Hold	8,416	–	–	0.02%	359
2022 Q3	$930K	Sell	8,416 -3,300	-28%	-$333K	0.02%	375
2022 Q2	$878K	Sell	11,716 -150	-1%	-$11K	0.02%	369
2022 Q1	$927K	Buy	11,866 +566	+5%	+$43.3K	0.02%	377
2021 Q4	$1.02M	Sell	11,300 -50	-0.4%	-$4.27K	0.02%	383
2021 Q3	$1.05M	Buy	11,350 +350	+3%	+$27K	0.02%	365
2021 Q2	$855K	Buy	11,000 +400	+4%	+$30.3K	0.02%	360
2021 Q1	$790K	Buy	10,600 +2,350	+28%	+$217K	0.02%	357
2020 Q4	$1.41M	Buy	+8,250	New	+$1.22M	0.04%	229
2016 Q1	–	Sell	-5,700	Closed	-$220K	–	333
2015 Q4	$220K	Buy	+5,700	New	+$185K	0.02%	314

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Peapack-Gladstone Financial Corp's SRPT Position: Q2 2025 in Review

Peapack-Gladstone Financial Corp sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 9,191 shares — an estimated $587K sold.

Peapack-Gladstone Financial Corp first reported a position in SRPT in Q4 2015 and held it in 19 quarters. The position peaked at $1.44M in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Peapack-Gladstone Financial Corp reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Peapack-Gladstone Financial Corp sold 9,191 Sarepta Therapeutics shares in Q2 2025, an estimated $587K.
Peapack-Gladstone Financial Corp first reported a position in Sarepta Therapeutics in Q4 2015 and held it in 19 quarters.
Peapack-Gladstone Financial Corp's Sarepta Therapeutics position peaked at $1.44M in Q2 2024.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q2 2025, filed 14 Aug 2025.